Trial Profile
An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-7117 After a Single Oral Dose to Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Dersimelagon (Primary)
- Indications Autoimmune disorders
- Focus Pharmacokinetics
- Acronyms MT-7117 MB
- Sponsors Mitsubishi Tanabe Pharma America
- 08 Jun 2018 Status changed from recruiting to completed.
- 23 Apr 2018 New trial record